Anti-phospholipase A2 receptor antibody and immunosuppression in membranous nephropathy: More evidence for pathogenicity of anti-phospholipase A2 receptor autoantibodies

Journal of the American Society of Nephrology

Volumn 26, Issue 10, 2015, Pages 2308-2311

  Brenchley, Paul E C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; STEROID; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOLOGIC FACTOR; PHOSPHOLIPASE A2 RECEPTOR;

ACTIN FILAMENT; CARDIOVASCULAR DISEASE; CIRCULATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CYTOLOGY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; GLOMERULUS BASEMENT MEMBRANE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INFECTION RISK; KIDNEY BIOPSY; KIDNEY FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MANAGED CARE; MEMBRANOUS GLOMERULONEPHRITIS; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PATHOGENICITY; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROTEINURIA; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TREATMENT DURATION; WESTERN BLOTTING; BLOOD; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; IMMUNOLOGY; MALE;

AUTOANTIBODIES; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOLOGIC FACTORS; MALE; RECEPTORS, PHOSPHOLIPASE A2; RITUXIMAB;

EID: 84942934166     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015020181     Document Type: Review

References (18)

1. Beck LH Jr., Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009.
2. Hofstra JM, Beck LH Jr., Beck DM, Wetzels JF, Salant DJ: Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286- 1291, 2011.
3. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF: Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1735-1743, 2012.
4. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, VenningM, Brenchley PE: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83: 940-948, 2013.
5. 2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9: 1386- 1392, 2014.
6. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am SocNephrol 25: 1357-1366, 2014.
7. Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA: M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 9: 1883-1890, 2014.
8. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, StöckerW, Schlumberger W: Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421: 213-218, 2013.
9. Ruggenenti P, DebiecH, RuggieroB, Chianca A, Pelle T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G: Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome ofmembranous nephropathy. J Am SocNephrol 26: 2545-2558, 2015.
10. Fresquet M, Jowitt TA, Gummadova J, Collins R, O'Cualain R, McKenzie EA, Lennon R, Brenchley PE: Identification of amajor epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol 26: 302-313, 2015.
11. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H: Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.Nephrol Dial Transplant 28: 1839-1844, 2013.
12. Tomas NM, Beck LH Jr., Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RA, Lambeau G: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371: 2277-2287, 2014.
13. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3: 85ra46, 2011.
14. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616-626, 2011.
15. Lv J, Hou W, Zhou X, Liu G, Zhou F, Zhao N, Hou P, Zhao M, Zhang H: Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol 24: 1323-1329, 2013.
16. Saeed M, Beggs ML, Walker PD, Larsen CP: PLA2R-associated membranous glomerulopathy is modulated by common variants in PLA2R1 and HLA-DQA1 genes. Genes Immun 15: 556-561, 2014.
17. Bullich G, Ballarín J, Oliver A, Ayasreh N, Silva I, Santín S, Díaz- Encarnación MM, Torra R, Ars E: HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy. Clin J Am Soc Nephrol 9: 335-343, 2014.
18. Coenen MJ, Hofstra JM, Debiec H, Stanescu HC, Medlar AJ, Stengel B, Boland-Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, Ronco P: Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol 24: 677-683, 2013.